Key result
Resveratrol lowers CRP and TNF-α, but not IL-6, in patients with cardiovascular disease.
Why the study?
Evidence regarding the effect of resveratrol on biomarkers of inflammation in patients with CVDs has been controversial.
Do resveratrol supplements reduce inflammatory biomarkers (TNF-α, IL-6, and CRP) in patients with cardiovascular disease?
Meta-Analysis
Do resveratrol supplements reduce inflammatory biomarkers (TNF-α, IL-6, and CRP) in patients with cardiovascular disease?
Effect estimate: MD -0.63 (95% CI -1.13, -0.12)
p-value: p=0.01
Resveratrol supplementation significantly reduces inflammatory biomarkers CRP and TNF-α, but not IL-6, in patients with cardiovascular disease.
Suggests resveratrol as adjunct to curb inflammation in CVD; extends biomarker evidence but needs outcome trials.
BACKGROUND: Chronic inflammation is one of the most important factors involved in the development and progression of cardiovascular disease (CVDs). Accumulating evidence has described the effect of resveratrol, a natural polyphenolic compound, on biomarkers of inflammation among patients with CVDs; however, findings are controversial. Here we performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of resveratrol supplements on TNF-α, IL-6, and CRP levels in CVDs patients. METHODS: Online research was conducted in the following database: MEDLINE, EMBASE, Cochrane Library, Web of Science databases, and Scopus. This systematic review and meta-analysis were conducted to investigate the effects of resveratrol supplements on inflammatory biomarkers among patients with CVDs. The meta-analysis was performed using Comprehensive Meta-Analysis (CMA) V3 software. RESULTS: Six RCTs met the inclusion criteria and were selected for the current meta-analysis. Our results demonstrated that resveratrol significantly decreases serum levels of CRP (MD = -0.63, 95 % CI: -0.1.13, -0.12; p = 0.01), and TNF-α (MD = -0.55, 95 % CI: -1.04, -0.06; p = 0.02), however, resveratrol had not significant effect on serum concentration of IL-6 (MD = -0.12, 95 % CI: -0.52, 0.27; p = 0.53), in patients with CVDs. CONCLUSION: Our results suggest that resveratrol can be used as a potential treatment in patients with CVD by reducing inflammatory conditions.
No takes yet. Share an insight, caveat, or question.
Teimouri et al. (2022) conducted a meta-analysis in Cardiovascular disease. Resveratrol supplements was evaluated on Serum levels of CRP (MD -0.63, 95% CI -1.13, -0.12, p=0.01). Resveratrol supplementation significantly decreased serum levels of CRP (MD -0.63; 95% CI -1.13 to -0.12; p=0.01) and TNF-α, but not IL-6, in patients with cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: